Cellectis (NASDAQ:CLLS) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Cellectis (NASDAQ:CLLS) in a research report sent to investors on Sunday. The brokerage issued a sell rating on the biotechnology company’s stock.

Cellectis Price Performance

CLLS opened at $3.10 on Friday. The company has a current ratio of 1.50, a quick ratio of 1.50 and a debt-to-equity ratio of 0.58. The stock has a market capitalization of $172.30 million, a P/E ratio of -1.80 and a beta of 3.08. The stock has a 50-day moving average price of $2.63 and a 200-day moving average price of $2.73. Cellectis has a 12-month low of $0.96 and a 12-month high of $3.77.

Cellectis (NASDAQ:CLLS) last posted its quarterly earnings results on Monday, April 29th. The biotechnology company reported ($0.64) EPS for the quarter. Cellectis had a negative return on equity of 99.88% and a negative net margin of 1,087.66%. The business had revenue of $1.99 million for the quarter. Equities analysts predict that Cellectis will post -1.06 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Cellectis stock. Principal Financial Group Inc. boosted its stake in Cellectis S.A. (NASDAQ:CLLS) by 6.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 424,533 shares of the biotechnology company’s stock after purchasing an additional 24,906 shares during the period. Principal Financial Group Inc. owned about 0.76% of Cellectis worth $1,125,000 at the end of the most recent reporting period. 63.90% of the stock is currently owned by institutional investors.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.